Inhibition of tumor glycolysis elevated available glucose levels in the TME and promoted the ability of CTLA-4 blockade to induce Treg cell fragility associated with IFN-γ production and development of anti-tumor immunity (210). This evidence concerns the gene CTLA4 and neoplasm.